|
GB401747A
(en)
*
|
1932-12-28 |
1933-11-23 |
Charles Hepburn Myrtle |
Method of and means for disinfecting air and distributing the treated air
|
|
US5672347A
(en)
|
1984-07-05 |
1997-09-30 |
Genentech, Inc. |
Tumor necrosis factor antagonists and their use
|
|
US4944796A
(en)
*
|
1988-11-14 |
1990-07-31 |
Ici Americas Inc. |
Certain 2-(disubstituted amino) acetanilide herbicides
|
|
US5540931A
(en)
|
1989-03-03 |
1996-07-30 |
Charles W. Hewitt |
Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
|
|
US4997950A
(en)
*
|
1989-04-20 |
1991-03-05 |
Richard Finbar Murphy |
Novel C-terminal gastrin antagonists
|
|
US5100899A
(en)
*
|
1989-06-06 |
1992-03-31 |
Roy Calne |
Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
|
|
US5958413A
(en)
|
1990-11-01 |
1999-09-28 |
Celltech Limited |
Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
|
|
US6420374B1
(en)
|
1990-11-30 |
2002-07-16 |
Fred Hutchinson Cancer Research Center |
Use of xanthines as immunosuppressants and to inhibit allograft reactions
|
|
US5861382A
(en)
|
1992-05-01 |
1999-01-19 |
Yeda Research And Development Co. Ltd. |
Methods for regulation of active TNF-α
|
|
US6270766B1
(en)
|
1992-10-08 |
2001-08-07 |
The Kennedy Institute Of Rheumatology |
Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
|
|
CA2146647C
(en)
|
1992-10-08 |
2009-05-05 |
Marc Feldmann |
Treatment of autoimmune and inflammatory disorders
|
|
US6645493B1
(en)
|
1993-05-17 |
2003-11-11 |
The Picower Institute For Medical Research |
Composition containing anti-MIF antibody
|
|
JPH09510952A
(ja)
|
1993-10-06 |
1997-11-04 |
ザ ケネディー インスティチュート オブ リューマトロジー |
自己免疫疾患および炎症性疾患の治療
|
|
NZ278607A
(en)
|
1994-02-07 |
1999-05-28 |
Knoll Ag |
Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
|
|
DE4430128A1
(de)
|
1994-08-25 |
1996-02-29 |
Hoechst Ag |
Kombinationspräparat mit immunsuppressiven, kardiovaskulären und cerebralen Wirkungen
|
|
DE4430127A1
(de)
|
1994-08-25 |
1996-03-14 |
Hoechst Ag |
Kombinationspräparat, enthaltend Cyclosporin A oder FK506 und ein Xanthinderivat
|
|
US5932737A
(en)
*
|
1994-12-02 |
1999-08-03 |
Fujisawa Pharmaceutical Co., Ltd. |
Peptide compounds for treatment of no-mediated diseases
|
|
US6306840B1
(en)
*
|
1995-01-23 |
2001-10-23 |
Biogen, Inc. |
Cell adhesion inhibitors
|
|
FR2730411B1
(fr)
*
|
1995-02-14 |
1997-03-28 |
Centre Nat Rech Scient |
Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes
|
|
US5654312A
(en)
|
1995-06-07 |
1997-08-05 |
Andrulis Pharmaceuticals |
Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents
|
|
ATE259235T1
(de)
|
1995-07-20 |
2004-02-15 |
Cell Eng Ag |
Zubereitung enthaltend glykane übereinstimmend mit transferrin glykaner als aktives prinzip für die induktion der immuntoleranz gegen antigene
|
|
IL115245A
(en)
|
1995-09-11 |
2002-12-01 |
Yissum Res Dev Co |
Tumor necrosis factor inhibiting pharmaceuticals
|
|
IL123431A
(en)
*
|
1995-11-22 |
2001-05-20 |
Darwin Discovery Ltd |
Mercaptoalkyl peptidil compounds with imidazole transducer and their use as metallic protonase matrix (MMP) compounds and / or tumor cause factor (TNF)
|
|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
|
US6211160B1
(en)
|
1996-09-06 |
2001-04-03 |
The Trustees Of The University Of Pennsylvania |
Method for tolerizing a mammalian patient to administration of gene therapy virus vectors
|
|
WO1998024463A2
(en)
|
1996-12-06 |
1998-06-11 |
Amgen Inc. |
Combination therapy using a tnf binding protein for treating tnf-mediated diseases
|
|
PL193966B1
(pl)
*
|
1997-01-10 |
2007-04-30 |
Biogen Idec Ma |
Zastosowanie przeciwciał przeciwko CD40L lub pochodnych
|
|
US6294170B1
(en)
|
1997-08-08 |
2001-09-25 |
Amgen Inc. |
Composition and method for treating inflammatory diseases
|
|
WO1998039026A2
(en)
|
1997-03-07 |
1998-09-11 |
Biogen, Inc. |
Methods of therapeutic administration of anti-cd40l compounds
|
|
US5801193A
(en)
|
1997-04-15 |
1998-09-01 |
Immune Modulation, Inc. |
Compositions and methods for immunosuppressing
|
|
US6506569B1
(en)
|
1997-05-30 |
2003-01-14 |
Human Genome Sciences, Inc. |
Antibodies to human tumor necrosis factor receptor TR10
|
|
US6503184B1
(en)
|
1997-10-21 |
2003-01-07 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
|
|
US6407218B1
(en)
*
|
1997-11-10 |
2002-06-18 |
Cytimmune Sciences, Inc. |
Method and compositions for enhancing immune response and for the production of in vitro mabs
|
|
US6359061B1
(en)
*
|
1999-03-19 |
2002-03-19 |
Isis Pharmaceuticals, Inc. |
Amide compound libraries
|
|
EP1165500A1
(en)
|
1999-04-02 |
2002-01-02 |
Du Pont Pharmaceuticals Company |
Amide derivatives as inhibitors of matrix metalloproteinases,tnf-alpha,and aggrecanase
|
|
US6204245B1
(en)
|
1999-09-17 |
2001-03-20 |
The Regents Of The University Of California |
Treatment of narcolepsy with immunosuppressants
|
|
AU1590201A
(en)
*
|
1999-11-09 |
2001-06-06 |
Chiron Corporation |
Compositions and methods for treating autoimmune diseases and transplant rejections
|
|
CA2781858C
(en)
*
|
2000-05-12 |
2015-03-31 |
Genzyme Corporation |
Modulators of tnf-.alpha. signaling
|
|
HUP0301932A3
(en)
|
2000-05-22 |
2007-09-28 |
Leo Pharma As |
Benzophenones as inhibitors of il-1 beta and tnf-alpha, pharmaceutical compositions containing them and use of them for producing pharmaceutical compositions
|
|
US20040072728A1
(en)
*
|
2002-06-26 |
2004-04-15 |
Fawwaz Rashid A. |
Use of streptavidin to inhibit transplant rejection
|
|
ATE520400T1
(de)
*
|
2002-11-21 |
2011-09-15 |
Genzyme Corp |
Kombination von einem diamidderivat und immunsuppressiva zur unterdrückung der transplantatabstossung
|
|
AU2003291134A1
(en)
*
|
2002-11-21 |
2004-06-18 |
Genzyme Corporation |
Use of diamide derivatives for inhibiting chronic tissue transplant rejection
|
|
EP2029729A2
(en)
*
|
2006-05-31 |
2009-03-04 |
Genzyme Corporation |
Methods of using anti-thymocyte globulin and related agents
|